ImmuneOnco is a science-driven biotechnology company at the forefront of developing next-generation immuno-oncology therapies. With a deep understanding of tumor immunology, we have built an integrated proprietary R&D engine, driving the discovery and development of innovative immunotherapies. Our comprehensive pipeline boasts over ten drug candidates targeting critical innate and adaptive immune checkpoints.

Among them, six are in clinical stage, one in IND stage, and one in IND-enabling stage. We currently have eight ongoing clinical programs, five IND/IND-enabling-stage programs, and multiple programs in the discovery and preclinical stages. Recent news includes the publication of preclinical research data of IMM0306 in the treatment of leukemia and the completion of patient enrollment for the phase II clinical study of IMM01 combined with azacitidine for high-risk myelodysplastic syndrome and acute myeloid leukemia.

At ImmuneOnco, we are committed to advancing the field of immuno-oncology and bringing hope to patients worldwide. Contact us for more information